DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Information source: Seth Gordhandas Sunderdas Medical College
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cushing's Disease; Corticotroph Adenoma

Intervention: Cabergoline (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Seth Gordhandas Sunderdas Medical College

Official(s) and/or principal investigator(s):
Nalini S Shah, DM, Principal Investigator, Affiliation: Seth GSMC and KEM hospital, Mumbai

Summary

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Clinical Details

Official title: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient with Cushing's disease uncured biochemically after pituitary surgery with

adenoma on histopathology Exclusion Criteria:

- Patient's intolerance to drug or known sensitivity to ergot derivatives

- Pregnancy, lactation or female wishing to be pregnant

- Any serious medical illness

- Patient on any drugs known to have an interaction with cabergoline including

antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Locations and Contacts

Seth GSMC & KEM hospital, Mumbai, Maharashtra 4000012, India
Additional Information

Starting date: November 2007
Last updated: April 28, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017